$ADAP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptimmune Therapeutics PLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Adaptimmune Therapeutics PLC. Get notifications about new insider transactions in Adaptimmune Therapeutics PLC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 28 2021 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Sell | S | 4.37 | 2,794 | 12,210 | 3,058 | 5.9 K to 3.1 K (-47.74 %) |
Mar 03 2021 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Buy | M | 0.16 | 1,785,000 | 280,245 | 1,800,000 | 15 K to 1.8 M (+11,900.00 %) |
Jan 19 2021 | ADAP | Adaptimmune Therap ... | Norry Elliot | Chief Medical Offic ... | Sell | S | 5.67 | 2,111 | 11,968 | 3,539 | 5.7 K to 3.5 K (-37.36 %) |
Jan 19 2021 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Sell | S | 5.67 | 4,358 | 24,708 | 7,346 | 11.7 K to 7.3 K (-37.24 %) |
Jan 19 2021 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Sell | S | 5.67 | 9,879 | 56,009 | 13,529 | 23.4 K to 13.5 K (-42.20 %) |
Jan 12 2021 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Sell | S | 6.15 | 2,234 | 13,744 | 3,768 | 6 K to 3.8 K (-37.22 %) |
Jan 12 2021 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Sell | S | 6.15 | 1,058 | 6,509 | 1,767 | 2.8 K to 1.8 K (-37.45 %) |
Jan 12 2021 | ADAP | Adaptimmune Therap ... | Norry Elliot | Chief Medical Offic ... | Sell | S | 6.15 | 841 | 5,174 | 1,396 | 2.2 K to 1.4 K (-37.59 %) |
Jan 12 2021 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Sell | S | 6.15 | 2,707 | 16,654 | 3,695 | 6.4 K to 3.7 K (-42.28 %) |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Wood Gavin | Chief Financial Off ... | Option Exercise | A | 0.00 | 242,712 | 340 | 242,712 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Wood Gavin | Chief Financial Off ... | Option Exercise | A | 1.03 | 1,086,816 | 1,119,420 | 1,086,816 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Norry Elliot | Chief Medical Offic ... | Option Exercise | A | 0.00 | 242,712 | 340 | 242,712 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Norry Elliot | Chief Medical Offic ... | Option Exercise | A | 1.03 | 1,086,816 | 1,119,420 | 1,086,816 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Option Exercise | A | 0.00 | 728,160 | 1,019 | 728,160 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Option Exercise | A | 1.03 | 3,260,400 | 3,358,212 | 3,260,400 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Option Exercise | A | 0.00 | 242,712 | 340 | 242,712 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Option Exercise | A | 1.03 | 1,086,816 | 1,119,420 | 1,086,816 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Option Exercise | A | 0.00 | 242,712 | 340 | 242,712 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Option Exercise | A | 1.03 | 1,086,816 | 1,119,420 | 1,086,816 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Option Exercise | A | 0.00 | 242,712 | 340 | 242,712 | |
Jan 11 2021 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Option Exercise | A | 1.03 | 1,086,816 | 1,119,420 | 1,086,816 | |
Jan 05 2021 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Sell | S | 5.33 | 1,065 | 5,674 | 1,760 | 2.8 K to 1.8 K (-37.70 %) |
Jan 05 2021 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Sell | S | 5.33 | 3,499 | 18,642 | 5,864 | 9.4 K to 5.9 K (-37.37 %) |
Jan 05 2021 | ADAP | Adaptimmune Therap ... | Norry Elliot | Chief Medical Offic ... | Sell | S | 5.33 | 845 | 4,502 | 1,392 | 2.2 K to 1.4 K (-37.77 %) |
Jan 05 2021 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Sell | S | 5.33 | 4,967 | 26,464 | 6,737 | 11.7 K to 6.7 K (-42.44 %) |
Dec 16 2020 | ADAP | Adaptimmune Therap ... | Wood Gavin | Chief Financial Off ... | Buy | P | 0.69 | 24,000 | 16,550 | 57,000 | 33 K to 57 K (+72.73 %) |
Dec 15 2020 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Buy | P | 0.69 | 207,000 | 143,824 | 284,808 | 77.8 K to 284.8 K (+266.04 %) |
Sep 02 2020 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Sell | S | 8.51 | 2,776 | 23,637 | 3,076 | 5.9 K to 3.1 K (-47.44 %) |
Aug 04 2020 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Sell | S | 9.25 | 2,788 | 25,789 | 3,064 | 5.9 K to 3.1 K (-47.64 %) |
Aug 04 2020 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Sell | S | 9.25 | 4,823 | 44,613 | 8,066 | 12.9 K to 8.1 K (-37.42 %) |
Aug 04 2020 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Sell | S | 8.74 | 200,000 | 1,748,180 | 0 | 200 K to 0 (-100.00 %) |
Jul 01 2020 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Option Exercise | A | 1.67 | 184,258 | 307,711 | 184,258 | |
Jul 01 2020 | ADAP | Adaptimmune Therap ... | Noble James | Director | Option Exercise | A | 1.67 | 179,785 | 300,241 | 179,785 | |
Jul 01 2020 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Option Exercise | A | 1.67 | 184,258 | 307,711 | 184,258 | |
Jul 01 2020 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 1.67 | 226,753 | 378,678 | 226,753 | |
Jul 01 2020 | ADAP | Adaptimmune Therap ... | Duncan Barbara Gayle | Director | Option Exercise | A | 1.67 | 144,000 | 240,480 | 144,000 | |
Jun 30 2020 | ADAP | Adaptimmune Therap ... | Wood Gavin | Chief Financial Off ... | Buy | P | 1.62 | 33,000 | 53,460 | 33,000 | 0 to 33 K |
Jun 30 2020 | ADAP | Adaptimmune Therap ... | Wood Gavin | Chief Financial Off ... | Buy | P | 1.62 | 33,000 | 53,460 | 33,000 | 0 to 33 K |
Jun 11 2020 | ADAP | Adaptimmune Therap ... | Alleva Lawrence M | Director | Buy | P | 1.89 | 12,900 | 24,381 | 12,900 | 0 to 12.9 K |
Jun 02 2020 | ADAP | Adaptimmune Therap ... | Noble James | Director | Sell | S | 9.33 | 500,000 | 4,666,000 | 0 | 500 K to 0 (-100.00 %) |
Apr 01 2020 | ADAP | Adaptimmune Therap ... | Noble James | Director | Option Exercise | A | 0.45 | 31,000 | 13,950 | 31,000 | |
Apr 01 2020 | ADAP | Adaptimmune Therap ... | Wood Gavin | Chief Financial Off ... | Option Exercise | A | 0.00 | 565,000 | 678 | 565,000 | |
Apr 01 2020 | ADAP | Adaptimmune Therap ... | Wood Gavin | Chief Financial Off ... | Option Exercise | A | 0.45 | 2,500,000 | 1,125,000 | 2,500,000 | |
Jan 28 2020 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | 12 M to 19.5 M (+62.50 %) |
Jan 28 2020 | ADAP | Adaptimmune Therap ... | Florence Anthony A. Jr. | 10% Owner | Buy | P | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | 12 M to 19.5 M (+62.50 %) |
Jan 28 2020 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Buy | P | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | 12 M to 19.5 M (+62.50 %) |
Jan 28 2020 | ADAP | Adaptimmune Therap ... | Sonsini Peter W. | 10% Owner | Buy | P | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | 12 M to 19.5 M (+62.50 %) |
Jan 28 2020 | ADAP | Adaptimmune Therap ... | BASKETT FOREST | 10% Owner | Buy | P | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | 12 M to 19.5 M (+62.50 %) |
Jan 28 2020 | ADAP | Adaptimmune Therap ... | SANDELL SCOTT D | 10% Owner | Buy | P | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | 12 M to 19.5 M (+62.50 %) |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | Norry Elliot | Chief Medical Offic ... | Option Exercise | A | 0.00 | 135,600 | 176 | 135,600 | |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | Norry Elliot | Chief Medical Offic ... | Option Exercise | A | 0.74 | 201,600 | 149,184 | 201,600 | |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Option Exercise | A | 0.00 | 280,896 | 365 | 280,896 | |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Option Exercise | A | 0.74 | 1,257,744 | 930,731 | 1,257,744 | |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Option Exercise | A | 0.00 | 280,896 | 365 | 280,896 | |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Option Exercise | A | 0.74 | 1,257,744 | 930,731 | 1,257,744 | |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Option Exercise | A | 0.00 | 280,896 | 365 | 280,896 | |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Option Exercise | A | 0.74 | 1,257,744 | 930,731 | 1,257,744 | |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Option Exercise | A | 0.00 | 561,792 | 730 | 561,792 | |
Jan 17 2020 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Option Exercise | A | 0.74 | 2,515,536 | 1,861,497 | 2,515,536 | |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Sell | S | 5.00 | 50,000 | 250,000 | 0 | 50 K to 0 (-100.00 %) |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Sell | S | 4.00 | 50,000 | 200,000 | 0 | 50 K to 0 (-100.00 %) |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Sell | S | 5.13 | 1,144 | 5,874 | 1,681 | 2.8 K to 1.7 K (-40.50 %) |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Sell | S | 5.13 | 3,236 | 16,616 | 3,166 | 6.4 K to 3.2 K (-50.55 %) |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | Noble James | Director | Sell | S | 5.00 | 200,000 | 1,000,000 | 0 | 200 K to 0 (-100.00 %) |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | Noble James | Director | Sell | S | 4.00 | 100,000 | 400,000 | 0 | 100 K to 0 (-100.00 %) |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | Norry Elliot | Chief Medical Offic ... | Sell | S | 5.13 | 911 | 4,678 | 1,326 | 2.2 K to 1.3 K (-40.72 %) |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Sell | S | 5.13 | 2,397 | 12,308 | 3,605 | 6 K to 3.6 K (-39.94 %) |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | Norry Elliot | Chief Medical Offic ... | Sell | S | 5.13 | 911 | 4,678 | 1,326 | 2.2 K to 1.3 K (-40.72 %) |
Jan 15 2020 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Sell | S | 5.13 | 2,397 | 12,308 | 3,605 | 6 K to 3.6 K (-39.94 %) |
Jan 07 2020 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Sell | S | 1.20 | 1,148 | 1,378 | 1,677 | 2.8 K to 1.7 K (-40.64 %) |
Jan 07 2020 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Sell | S | 1.20 | 3,731 | 4,477 | 5,632 | 9.4 K to 5.6 K (-39.85 %) |
Jan 07 2020 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Executive Off ... | Sell | S | 1.20 | 5,900 | 7,080 | 5,804 | 11.7 K to 5.8 K (-50.41 %) |
Sep 03 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | CEO and CFO | Option Exercise | A | 0.00 | 140,448 | 169 | 140,448 | |
Sep 03 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | CEO and CFO | Option Exercise | A | 0.00 | 140,448 | 169 | 140,448 | |
Sep 03 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | CEO and CFO | Option Exercise | A | 0.27 | 628,872 | 169,795 | 628,872 | |
Sep 03 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | CEO and CFO | Option Exercise | A | 0.27 | 628,872 | 169,795 | 628,872 | |
Aug 07 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R&D | Sell | S | 2.06 | 11,043 | 22,749 | 17,237 | 28.3 K to 17.2 K (-39.05 %) |
Aug 05 2019 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Option Exercise | A | 0.00 | 187,500 | 225 | 187,500 | |
Aug 05 2019 | ADAP | Adaptimmune Therap ... | Lunger John | Chief Patient Suppl ... | Option Exercise | A | 0.55 | 839,568 | 461,762 | 839,568 | |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 0.61 | 350,947 | 214,078 | 350,947 | |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Option Exercise | A | 0.61 | 234,407 | 142,988 | 234,407 | |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | Zaks Tal Zvi | Director | Option Exercise | A | 0.61 | 124,000 | 75,640 | 124,000 | |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Option Exercise | A | 0.61 | 234,407 | 142,988 | 234,407 | |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | Furey John | Director | Option Exercise | A | 0.61 | 240,541 | 146,730 | 240,541 | |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | Kerr Giles Francis Bertram | Director | Option Exercise | A | 0.61 | 124,000 | 75,640 | 124,000 | |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | Duncan Barbara Gayle | Director | Option Exercise | A | 0.61 | 124,000 | 75,640 | 124,000 | |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | Alleva Lawrence M | Director | Option Exercise | A | 0.61 | 271,209 | 165,437 | 271,209 | |
Jun 27 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Financial Off ... | Option Exercise | A | 0.00 | 140,448 | 183 | 140,448 | |
Jun 27 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Financial Off ... | Option Exercise | A | 0.68 | 628,872 | 427,633 | 628,872 | |
May 17 2019 | ADAP | Adaptimmune Therap ... | Noble James | Chief Executive Off ... | Buy | M | 0.14 | 1,773,100 | 253,553 | 1,773,100 | 0 to 1.8 M |
Jan 16 2019 | ADAP | Adaptimmune Therap ... | Binder-Scholl Gwendolyn Knowlt ... | Chief Technology Of ... | Sell | S | 5.37 | 1,514 | 8,129 | 2,487 | 4 K to 2.5 K (-37.84 %) |
Jan 16 2019 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Sell | S | 5.37 | 2,271 | 12,194 | 3,731 | 6 K to 3.7 K (-37.84 %) |
Jan 16 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Sell | S | 5.37 | 3,028 | 16,259 | 4,974 | 8 K to 5 K (-37.84 %) |
Jan 16 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Financial Off ... | Sell | S | 5.37 | 3,084 | 16,559 | 3,318 | 6.4 K to 3.3 K (-48.17 %) |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Option Exercise | A | 0.00 | 224,724 | 292 | 224,724 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Option Exercise | A | 0.00 | 224,724 | 292 | 224,724 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Option Exercise | A | 0.89 | 1,006,224 | 895,539 | 1,006,224 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Bertrand William C JR | Chief Operating Off ... | Option Exercise | A | 0.89 | 1,006,224 | 895,539 | 1,006,224 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Option Exercise | A | 0.00 | 224,724 | 292 | 224,724 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Option Exercise | A | 0.00 | 224,724 | 292 | 224,724 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Option Exercise | A | 0.89 | 1,006,224 | 895,539 | 1,006,224 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | TAYTON-MARTIN HELEN KATRINA | Chief Business Offi ... | Option Exercise | A | 0.89 | 1,006,224 | 895,539 | 1,006,224 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Financial Off ... | Option Exercise | A | 0.00 | 280,896 | 365 | 280,896 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Financial Off ... | Option Exercise | A | 0.00 | 280,896 | 365 | 280,896 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Financial Off ... | Option Exercise | A | 0.89 | 1,257,744 | 1,119,392 | 1,257,744 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Financial Off ... | Option Exercise | A | 0.89 | 1,257,744 | 1,119,392 | 1,257,744 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.00 | 224,724 | 292 | 224,724 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.00 | 224,724 | 292 | 224,724 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.89 | 1,006,224 | 895,539 | 1,006,224 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.89 | 1,006,224 | 895,539 | 1,006,224 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Noble James | Chief Executive Off ... | Option Exercise | A | 0.00 | 561,792 | 730 | 561,792 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Noble James | Chief Executive Off ... | Option Exercise | A | 0.00 | 561,792 | 730 | 561,792 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Noble James | Chief Executive Off ... | Option Exercise | A | 0.89 | 2,515,536 | 2,238,827 | 2,515,536 | |
Jan 08 2019 | ADAP | Adaptimmune Therap ... | Noble James | Chief Executive Off ... | Option Exercise | A | 0.89 | 2,515,536 | 2,238,827 | 2,515,536 | |
Dec 19 2018 | ADAP | Adaptimmune Therap ... | Alleva Lawrence M | Director | Buy | P | 0.84 | 47,280 | 39,715 | 47,280 | 0 to 47.3 K |
Dec 19 2018 | ADAP | Adaptimmune Therap ... | Alleva Lawrence M | Director | Buy | P | 0.84 | 47,280 | 39,715 | 47,280 | 0 to 47.3 K |
Oct 02 2018 | ADAP | Adaptimmune Therap ... | Binder-Scholl Gwendolyn Knowlt ... | Chief Technology Of ... | Sell | S | 13.79 | 25,000 | 344,750 | 0 | 25 K to 0 (-100.00 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | Viswanathan Ravi | 10% Owner | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | Viswanathan Ravi | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | Sonsini Peter W. | 10% Owner | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | Sonsini Peter W. | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | SANDELL SCOTT D | 10% Owner | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | SANDELL SCOTT D | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | KERINS PATRICK J | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | Florence Anthony A. Jr. | 10% Owner | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | Florence Anthony A. Jr. | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | BASKETT FOREST | 10% Owner | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | BASKETT FOREST | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | BARRIS PETER J | 10% Owner | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | BARRIS PETER J | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | BARRETT M JAMES | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Aug 31 2018 | ADAP | Adaptimmune Therap ... | Binder-Scholl Gwendolyn Knowlt ... | Chief Technology Of ... | Sell | S | 10.25 | 25,000 | 256,250 | 0 | 25 K to 0 (-100.00 %) |
Aug 07 2018 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.00 | 678,720 | 882 | 678,720 | |
Jun 26 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 2.18 | 187,330 | 408,379 | 187,330 | |
Jun 26 2018 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Option Exercise | A | 2.18 | 154,809 | 337,484 | 154,809 | |
Jun 26 2018 | ADAP | Adaptimmune Therap ... | Kerr Giles Francis Bertram | Director | Option Exercise | A | 2.18 | 124,000 | 270,320 | 124,000 | |
Jun 26 2018 | ADAP | Adaptimmune Therap ... | Alleva Lawrence M | Director | Option Exercise | A | 2.18 | 124,000 | 270,320 | 124,000 | |
Jun 26 2018 | ADAP | Adaptimmune Therap ... | Zaks Tal Zvi | Director | Option Exercise | A | 2.18 | 124,000 | 270,320 | 124,000 | |
Jun 26 2018 | ADAP | Adaptimmune Therap ... | Duncan Barbara Gayle | Director | Option Exercise | A | 2.18 | 158,233 | 344,948 | 158,233 | |
Jun 26 2018 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Option Exercise | A | 2.18 | 154,809 | 337,484 | 154,809 | |
Jun 06 2018 | ADAP | Adaptimmune Therap ... | Thompson Peter A. | Director | Sell | S | 13.49 | 1,600 | 21,584 | 4,901,310 | 4.9 M to 4.9 M (-0.03 %) |
Jun 06 2018 | ADAP | Adaptimmune Therap ... | Thompson Peter A. | Director | Sell | S | 13.57 | 17,100 | 232,047 | 4,902,910 | 4.9 M to 4.9 M (-0.35 %) |
Jun 06 2018 | ADAP | Adaptimmune Therap ... | ORBIMED ADVISORS LLC | Director | Sell | S | 13.49 | 1,600 | 21,584 | 4,901,310 | 4.9 M to 4.9 M (-0.03 %) |
Jun 06 2018 | ADAP | Adaptimmune Therap ... | ORBIMED ADVISORS LLC | Director | Sell | S | 13.57 | 17,100 | 232,047 | 4,902,910 | 4.9 M to 4.9 M (-0.35 %) |
Jun 01 2018 | ADAP | Adaptimmune Therap ... | Thompson Peter A. | Director | Sell | S | 13.49 | 50,000 | 674,500 | 4,920,010 | 5 M to 4.9 M (-1.01 %) |
Jun 01 2018 | ADAP | Adaptimmune Therap ... | Thompson Peter A. | Director | Sell | S | 13.52 | 121,000 | 1,635,920 | 4,970,010 | 5.1 M to 5 M (-2.38 %) |